Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy have shown significant clinical benefits in terms of progression-free survival (PFS) and overall survival (OS) for hormone receptor (HR)-positive advanced breast cancer. This evidence concerns the gene NR4A1 and breast carcinoma.